ALT vs VKTX vs TERN vs GPCR vs NVO

For growth investors, Altimmune, Inc.

(ALT) is the stronger pick with 105. 0% revenue growth year-over-year, versus 6. 4% for Novo Nordisk A/S (NVO). Novo Nordisk A/S (NVO) offers the better valuation at 12. 6x trailing P/E (2. 1x forward), making it the more compelling value choice. Analysts rate Altimmune, Inc. (ALT) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Viking Therapeutics, Inc.

(VKTX) delivered a total return of +435. 3%, compared to -77. 1% for Altimmune, Inc. (ALT). Over 10 years, the gap is even starker: VKTX returned +25. 8% versus GPCR's +50. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Terns Pharmaceuticals, Inc.

(TERN) is the lower-risk stock at 0. 39β versus Viking Therapeutics, Inc. 's 1. 61β — meaning VKTX is approximately 307% more volatile than TERN relative to the S&P 500. On balance sheet safety, Viking Therapeutics, Inc. (VKTX) carries a lower debt/equity ratio of 0% versus 67% for Novo Nordisk A/S — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Altimmune, Inc.

(ALT) is pulling ahead at 105. 0% versus 6. 4% for Novo Nordisk A/S (NVO). On earnings-per-share growth, the picture is similar: Altimmune, Inc. grew EPS 25. 4% year-over-year, compared to -215. 8% for Viking Therapeutics, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Novo Nordisk A/S (NVO) is the more profitable company, earning 33.

1% net margin versus -2148. 6% for Altimmune, Inc. — meaning it keeps 33. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NVO leads at 41. 3% versus -2304. 6% for ALT. At the gross margin level — before operating expenses — NVO leads at 81. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for ALT: 270.

1% to $11. 25.

In this comparison, NVO (4.

0% yield) pays a dividend. ALT, VKTX, TERN, GPCR do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Terns Pharmaceuticals, Inc.

(TERN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 39), +187. 9% 10Y return). Viking Therapeutics, Inc. (VKTX) carries a higher beta of 1. 61 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (TERN: +187. 9%, VKTX: +25. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: ALT is a small-cap high-growth stock; VKTX is a small-cap quality compounder stock; TERN is a small-cap quality compounder stock; GPCR is a small-cap quality compounder stock; NVO is a large-cap deep-value stock. NVO pays a dividend while ALT, VKTX, TERN, GPCR do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.